BTK and diffuse large B-cell lymphoma: Among a cohort of 39 DLBCL patients for whom both Bcl-2 expression and nuclear P65 localization were evaluable by immunohistochemistry, 18 (46%) had strong Bcl-2 expression in more than 70% of tumor B-cells (Fig. 4i); of these, 6 (33%) had either weakly (4) or moderately (2) positive nuclear P65 signals (Fig. 4i), and would therefore be predicted to benefit from combined Bcl-2/BTK inhibition.